NEW YORK (GenomeWeb News) — Nanotechnology company Lumera yesterday said it has extended a collaboration with the Medical University of South Carolina to develop a mitochondrial protein-expression array.
The agreement grants Lumera the rights to commercialize all jointly developed intellectual property, the company said.
Lumera said the array will “measure the levels and modifications of patient mitochondrial proteins.” Changes in these proteins may be used as markers for “certain pathologies,” the company added.
The company said the assay will “have significant time and cost advantages over existing technologies.”
Lumera makes a Proteomic Processor instrument and NanoCapture microarray slides used to measure thousands of proteins simultaneously.
The collaboration will continue to develop the work of MUSC lead investigator Craig Beeson, the company said. “[W]hile academically interesting, this project has implications across pharma that are significant,” Timothy Londergan, Lumera’s bioscience business unit director said in a statement.